Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to -$2.1 million.

  • Ekso Bionics Holdings' Cash from Operations rose 948.62% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.9 million, marking a year-over-year increase of 1094.33%. This contributed to the annual value of -$9.8 million for FY2024, which is 1831.76% up from last year.
  • As of Q3 2025, Ekso Bionics Holdings' Cash from Operations stood at -$2.1 million, which was up 948.62% from -$3.4 million recorded in Q2 2025.
  • Over the past 5 years, Ekso Bionics Holdings' Cash from Operations peaked at -$1.4 million during Q4 2024, and registered a low of -$4.2 million during Q2 2022.
  • Its 5-year average for Cash from Operations is -$2.9 million, with a median of -$2.9 million in 2023.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 11030.0% in 2022, then soared by 5653.13% in 2023.
  • Ekso Bionics Holdings' Cash from Operations (Quarter) stood at -$3.1 million in 2021, then dropped by 18.5% to -$3.6 million in 2022, then soared by 56.53% to -$1.6 million in 2023, then grew by 9.53% to -$1.4 million in 2024, then tumbled by 43.82% to -$2.1 million in 2025.
  • Its Cash from Operations was -$2.1 million in Q3 2025, compared to -$3.4 million in Q2 2025 and -$2.0 million in Q1 2025.